

“Taking the Legacy of
Ayurveda ahead,
Scientifically...”



AIMIL
PHARMACEUTICALS



ANNUAL REPORT
2018-19





INDEPENDENT AUDITOR'S REPORT

To,

The Members of

AIMIL PHARMACEUTICALS (INDIA) LIMITED

Opinion

We have audited the accompanying financial statements of **AIMIL PHARMACEUTICALS (INDIA) LIMITED** which comprise the Balance Sheet as at 31st March 2019, the Statement of Profit & Loss Account (including other Comprehensive Income), the Statement of Changes of Equity and the Statement of Cash Flow Statement for the year then ended and a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us and on the basis of documents produced before us, the aforesaid Ind AS financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the company as at March 31, 2019, its Profit/Loss, Total Comprehensive Income/Loss, its cash flows and changes in the equity for the year ended on that date.

Basis for Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independent requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Key Audit Matters

Key audit matters are those matters that, in the auditor's professional judgment, were of most significance in the audit of the financial statements of the current period. These matters were addressed in the context of the audit of the financial statements as a whole, and in forming the auditor's opinion thereon, and the auditor does not provide a separate opinion on these matters. Reporting of key audit matters as per SA 701, Key Audit Matters are not applicable to the Company as it is an unlisted company.

Information Other than the Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Management Discussion and Analysis, Board's Report including Annexure to Board's Report, Business Responsibility Report, Corporate Governance and Shareholder's Information, but does not include the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our Knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.



Page No. 1

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance, total comprehensive income, changes in equity and cash flows of the Company in accordance with the Ind AS and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility for the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.



We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

I. As required by section 143 (3) of the Act, we report that:

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
- b) In our opinion proper books of account as required by law have been kept by the company so far as appears from our examination of those books;
- c) The Balance Sheet, Statement of Profit & Loss including Other Comprehensive Income, the Cash Flow Statement and Statement of Changes in Equity dealt with by this Report are in agreement with the books of account;
- d) In our opinion, the aforesaid financial statements comply with the applicable Accounting Standards specified under Section 133 the Act;
- e) On the basis of written representations received from the directors as on March 31, 2019, and taken on record by the Board of Directors, none of the Directors is disqualified as on March 31, 2019, from being appointed as a director in terms of Section 164(2) of the Act.
- f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "Annexure-II"; and
- g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended: In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act
- h) In our opinion and to the best of our information and according to the explanations given to us, we report as under with respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditor's) Rules, 2014:
 - (i) The company has no pending litigations on its financial position in its Financial Statements.
 - (ii) The Company does not have any material foreseeable losses on long-term contracts including derivative contracts.
 - (iii) There has been no delay in transferring amounts, required to be transferred, to Investor Education and Protection Fund by the Company.

II. As required by the Companies (Auditor's Report) Order, 2016 ("the order") issued by the Central Government of India in terms of sub section (11) of Section 143 of the Act, we enclose in the "Annexure I", a statement on the matters specified in Clause's 3 and 4 of the Order.

Place: Delhi
Date: 28.06.2019



For Ambani & Associates LLP
Chartered Accountant
FRN-016923N

(Hitesh Ambani), M.N. -506267

Designated Partner

Annexure-I to the Independent Auditors' Report

The Annexure referred to in Independent Auditor's Report to the members of the Company on the financial statements for the year ended 31st March, 2019, we report that:

1. In Respect of Fixed Assets

(a) The company has maintained proper records showing full particulars including quantitative details and situation of fixed assets.

(b) All fixed assets were physically verified by the management in the current year in accordance with a planned program of verifying them once in two years which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. No material discrepancies were noticed on such verification.

2. In Respect of Inventory

(a) The management has conducted physical verification of inventory at reasonable intervals during the year.

(b) Procedures for physical verification of inventory followed by the management is reasonable and adequate in relation to the size of the company and the nature of its business. There are no inadequacies in such procedures that should be reported.

(c) The company is maintaining proper records of inventory and no material discrepancies were noticed on physical verification carried out at the end of the year.

3. Loans and advances to parties covered under section 189

As informed, the company has not granted any loans secured or unsecured to companies, Limited Liability Partnership, firms or other parties covered in the register maintained under section 189 of the Companies Act, 2013.

4. Internal Control in reference to Purchase of Inventory and Fixed Assets and whether there is continue failure of Internal control

In our opinion and according to the information and explanations given to us there is adequate internal control system commensurate with the size of the company and the nature of its business for the purchase of inventory and fixed assets and for the sale of goods. During the course of audit We have not observed continuing failure to correct major weaknesses in internal control system.

5. Rules followed while accepting Deposits

No deposits within the meaning of Sections 73 to 76 or any other relevant provision of the Act and rules framed there under have been accepted by the Company.

6. Maintenance of cost records

We have broadly reviewed the books of accounts relating to materials, labour and other items of cost maintained by the company pursuant to the Rules made by the Central Government for the maintenance of cost records under sub-section (I) of section 148 of the Companies Act, 2013 and we are of the opinion that prima facie the prescribed accounts and records have been made and maintained.

7. According to the information and explanations given to us in respect of statutory dues

(a) As per the records of the company, the company has regularly deposited provident fund dues and the Employees State Insurance dues with the appropriate authorities.

(b) As per the records of the company, the company, statutory liabilities outstanding, at the year end, for a period of more than six months from the date they became payable are mentioned in Schedule 2 - Notes to Accounts.



8. **Company which has been registered for a period less than five years and accumulated losses are more than 50% of Net worth, Reporting of cash Losses**

The company has no accumulated losses at March 31st, 2019 and has not incurred cash losses in the current and immediately preceding financial year.

9. **Default in Repayment of Loans taken from Bank or Financial Institutions**

The company has not defaulted in repayment of dues to financial institution or bank.

10. **Terms for Loans and Advances from Banks or Financial Institutions prejudicial to the interest of the company**

On the basis of records examined by us and information provided by the management, we are of the opinion that the company has not given guarantees for loans taken by other from banks or financial institutions.

11. **Application versus purpose for which Loan Granted**


Based on information and explanations given to us by the management, term loans were applied for the purpose for which the loans were obtained.

12. **Reporting of Fraud During the Year Nature and Amount**

Based upon the audit procedures performed for the purpose of recording the true and fair view of the financial statements and as per the information and explanations given by the management, we report that no fraud by the company has been noticed or reported during the course of our audit.

Place: Delhi
Date: 28.06.2019

For Ambani & Associates LLP
Chartered Accountant
FRN-016923N



(Signature)
(Hitesh Ambani), M.N. -506267
Designated Partner

Annexure – II to the Independent Auditors' Report

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **AIMIL PHARMACEUTICALS (INDIA) LIMITED** as of 31st March, 2019 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on

our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.




Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31st March 2019, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

Place: Delhi
Date: 28.06.2019

For Ambani & Associates LLP
Chartered Accountant
FRN-016923N



(Hitesh Ambani), M.N. -506267
Designated Partner

"जय माता दी"



AIMIL PHARMACEUTICALS (INDIA) LIMITED

2994/4, STREET NO-17, RANJEET NAGAR, NEW DELHI - 110008

CIN - U24231DL1984PLC019461

BALANCE SHEET AS AT 31st MARCH, 2019

	PARTICULARS	SCH.	AS AT 31.03.2019	AS AT 31.03.2018
I	EQUITY AND LIABILITIES			
1	SHAREHOLDER'S FUNDS			
	Share Capital	3	13,17,56,000	13,17,56,000
	Reserves and Surplus	4	16,97,85,266	13,50,00,177
2	NON CURRENT LIABILITIES			
	(a) Long-Term Borrowings	5	43,42,51,428	35,02,84,430
	(b) Deferred Tax Liabilities (Net)	6	33,49,525	38,30,900
3	CURRENT LIABILITIES			
	(a) Short-Term Borrowings	7	41,84,63,489	35,58,34,869
	(b) Trade Payables	8	28,99,35,054	24,71,73,350
	(c) Other Current Liabilities	9	19,04,62,162	14,95,78,647
	(d) Short Term Provisions	10	3,02,54,032	2,30,11,588
	TOTAL Rs...		1,66,82,56,957	1,39,64,69,961
II	ASSETS			
1	NON-CURRENT ASSETS	11		
	Fixed Assets :			
	(a) Tangible Assets		23,87,72,810	25,58,72,050
	(b) Intangible Assets		7,079	0
2	CURRENT ASSETS			
	(a) Inventories	12	20,28,16,374	31,69,03,318
	(b) Trade Receivables	13	1,02,62,91,858	68,47,95,524
	(c) Cash and Cash Equivalents	14	1,02,35,963	75,79,071
	(d) Short-Term Loans and Advances	15	19,01,32,875	13,13,19,998
	TOTAL Rs...		1,66,82,56,957	1,39,64,69,961
	SIGNIFICANT ACCOUNTING POLICIES	1	0	0
	NOTES TO THE ACCOUNTS	2		

As Per Our Report of Even Date Attached

Ambani & Associates LLP

Chartered Accountants

FRN - 016923N

Hitesh Ambani

Hitesh Ambani

Designated Partner

(MN-506267)



For and on behalf of the Board

Kanwal Kumar Sharma

Kanwal Kumar Sharma

(Managing Director)

DIN - 00526387

Pankaj Marwaha

Pankaj Marwaha

(Director - Marketing)

DIN - 00526342

Ram Sawroop Sharma

Ram Sawroop Sharma

(Chief Financial Officer)



Place: New Delhi

Date: 28.06.2019



AIMIL PHARMACEUTICALS (INDIA) LIMITED
2994/4, STREET NO-17, RANJEET NAGAR, NEW DELHI - 110008
CIN - U24231DL1984PLC019461

PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 31st March, 2019

PARTICULARS	SCH.	YEAR ENDED 31.03.2019	YEAR ENDED 31.03.2018
INCOME			
Revenue from operations (gross)	16	3,04,58,50,694	2,82,00,70,222
Less : Excise duty		0	59,60,625
Revenue from operations (net)		3,04,58,50,694	2,81,41,09,596
Other income	17	1,03,49,992	1,22,31,549
Total Revenue		3,05,62,00,686	2,82,63,41,145
EXPENDITURE			
Cost of Materials Consumed	18	44,85,84,623	56,65,25,147
Purchases of Stock -in-Trade		24,27,22,862	9,42,60,418
Changes in Inventories of Finished Goods and Stock-in-Process	19	12,96,55,315	5,76,93,521
Employee Benefits Expense	20	59,43,42,852	56,01,30,735
Other Expenses	21	1,46,85,08,209	1,40,43,17,543
Finance Costs	22	8,74,88,259	6,16,05,304
Depreciation		3,77,01,411	4,13,27,289
Total Expenses		3,00,90,03,532	2,78,58,59,957
Profit Before Extra-ordinary Items & Tax		4,71,97,154	4,04,81,189
Less : Extra-Ordinary Items		0	0
Additional Depreciation due to change of useful life of assets			
Profit Before Tax		4,71,97,154	4,04,81,189
Tax Expenses			
Current Tax		1,00,00,000	90,00,000
Deferred tax		-4,81,375	-19,29,810
Total Tax Expenses		95,18,625	70,70,190
Profit for the year		3,76,78,529	3,34,10,999

As Per Our Report of Even Date Attached

Ambani & Associates LLP

Chartered Accountants

FRN - 016923N

Hitesh Ambani

Designated Partner

(MN-506267)

UDIN:



For and on behalf of the Board


Kanwal Kumar Sharma

Kanwal Kumar Sharma
(Managing Director)
DIN - 00526387

Pankaj Marwaha

Pankaj Marwaha
(Director - Marketing)
DIN - 00526342

Ram Sawroop Sharma
(Chief Financial Officer)



Place: New Delhi

Date: 28.06.2019



AIMIL PHARMACEUTICALS (INDIA) LIMITED

	AS AT 31.03.2019	AS AT 31.03.2018
SCHEDULE - 3 : SHARE CAPITAL		
AUTHORISED		
9,50,000 (Previous Year 9,50,000) Equity Shares of Rs. 100/- each	9,50,00,000	9,50,00,000
5,00,000 (Previous Year 5,00,000) Preference Shares Rs. 100/- each	5,00,00,000	5,00,00,000
ISSUED, SUBSCRIBED & PAID UP		
8,17,560 (Previous Year 8,17,560) Equity Shares of Rs 100/- each fully paid up	8,17,56,000	8,17,56,000
(out of these 3,300 (Prev. Year 3,300) equity shares were issued for consideration other than cash)		
5,00,000, 8% Redeemable Preference Shares (Previous Year 5,00,000) of Rs. 100/- each fully paid up	5,00,00,000	5,00,00,000
	13,17,56,000	13,17,56,000
SCHEDULE - 4 : RESERVES AND SURPLUS		
General Reserve	5,16,745	5,16,745
Securities Premium Account	64,80,000	64,80,000
Surplus in Statement of Profit and Loss		
As per last Balance Sheet	12,80,03,432	9,74,81,112
Profit for the period	3,76,78,529	3,34,10,904
Less : Appropriations for Preference Dividend	24,00,000	24,00,000
Tax on Dividend	4,93,440	4,88,584
	16,27,88,521	12,80,03,432
	16,97,85,266	13,50,00,177
SCHEDULE - 5 : LONG TERM BORROWINGS		
a) Security Deposit	36,46,28,616	27,50,24,370
b) From Punjab National Bank	5,97,51,166	6,36,86,194
Secured against equitable mortgage of immovable properties of Nalagarh		
Unit and personal guarantee of Directors		
Add : Interest accrued and but not due	98,71,646	1,15,73,866
c) From Punjab National Bank		
Secured against hypothentication of Vehicles		
	43,42,51,428	35,02,84,430
SCHEDULE - 6 : DEFERRED TAX LIABILITIES		
Deferred Tax Liabilities	33,49,525	38,30,900
	33,49,525	38,30,900


Guarantee
Paruaha



**AIMIL PHARMACEUTICALS (INDIA) LIMITED**

	AS AT 31.03.2019	AS AT 31.03.2018
SCHEDULE - 7 : SHORT - TERM BORROWINGS		
From Bank		
Secured against Hypothecation of stocks, Debtors including Govt. Bills, equitable mortgage on immovable properties, plant & machinery of existing unit and personal guarantee of Directors.	41,84,63,489	35,58,34,869
	41,84,63,489	35,58,34,869
SCHEDULE - 8 : TRADE PAYABLES		
Sundry Creditors		
- Due to small scale industries	45,75,437	22,45,310
- Others	28,53,59,617	24,49,28,040
	28,99,35,054	24,71,73,350
SCHEDULE - 9 : OTHER CURRENT LIABILITIES		
Other liabilities	19,04,62,162	14,95,78,647
	19,04,62,162	14,95,78,647
SCHEDULE - 10 : SHORT - TERM PROVISIONS		
Provision for Income Tax	3,02,54,032	2,30,11,588
	3,02,54,032	2,30,11,588
SCHEDULE - 12 : INVENTORIES (As verified and certified by the management)		
Raw Material	6,89,68,468	5,66,74,726
Work in Process	2,96,03,030	2,57,01,584
Packing Material	4,16,40,759	3,95,08,834
Finished Goods	6,10,05,080	15,09,80,028
Goods In Transit	12,27,130	4,09,07,498
Stock of Literature & other Items	3,71,906	31,30,648
	20,28,16,374	31,69,03,318
SCHEDULE - 13 : TRADE RECEIVABLES (Unsecured, Considered good) Outstanding for a period exceeding six months Others	3,95,45,620 98,67,46,238 1,02,62,91,858	3,72,87,050 64,75,08,474 68,47,95,524
SCHEDULE - 14 : CASH AND CASH EQUIVALENTS		
Cash in Hand	31,90,079	17,74,414
Bank Balances with Scheduled Banks		
--In Current accounts	26,00,487	30,09,260
--Cheques In Transit	-	-
--Fixed Deposits	44,45,397	27,95,397
	1,02,35,963	75,79,071

Dr. Anand
Dr. Anand



**AIMIL PHARMACEUTICALS (INDIA) LIMITED****SCHEDULE 11 : SCHEDULE OF FIXED ASSETS AND DEPRECIATION THEREON FOR THE YEAR ENDED 31st March, 2019**

	GROSS BLOCK				DEPRECIATION				NET BLOCK		
	As At 01.04.2018	Additions	Sale Adjustment	As At 31.03.2019	Upto 31.03.2018	For the Year		Sale Adjustment	Upto 31.03.2019	As At 31.03.2019	As At 31.03.2018
						Additional	Current				
A. Land	84,07,000	0	0	84,07,000	0	0	0	0	0	84,07,000	84,07,000
B. Building	19,40,37,696	1,05,13,086	0	20,45,50,782	7,24,66,280	0	1,22,95,201	0	8,47,61,481	11,97,89,301	12,15,71,416
C. Plant & Machinery	23,52,55,190	55,82,637	0	24,08,37,827	13,96,34,325	0	1,52,13,788	0	15,48,48,113	8,59,89,714	9,56,20,865
D. Computers	1,50,09,806	23,57,504	0	1,73,67,310	1,00,14,980	0	39,46,138	0	1,39,61,118	34,06,192	49,94,826
E. Vehicles	5,35,30,339	0	0	5,35,30,339	4,15,65,118	0	34,42,459	0	4,50,07,577	85,22,762	1,19,65,221
F. Furniture & Fixtures	1,45,98,815	66,84,578	0	2,12,83,393	1,10,31,257	0	10,02,124	0	1,20,33,381	92,50,012	35,67,558
G. Office Equipment	1,35,36,119	12,81,494	0	1,48,17,613	99,53,469	0	17,62,753	0	1,17,16,222	31,01,391	35,82,650
H. Electric equipment	7,65,505	0	0	7,65,505	7,14,561	0	0	0	7,14,561	50,944	50,944
I. Cable Wires	36,53,555	1,73,424	0	38,26,979	35,32,538	0	38,947	0	35,71,485	2,55,494	1,21,017
TOTAL (A)	53,87,94,025	2,65,92,724	0	56,53,86,749	28,89,12,528	0	3,77,01,411	0	32,66,13,939	23,87,72,810	24,98,81,497
Capital Work in Progress	59,90,557	0	59,90,557	0	0	0	0	0	0	0	59,90,557
TOTAL (B)	59,90,557	0	59,90,557	0	0	0	0	0	0	0	59,90,557
TOTAL (A+B)	54,47,84,582	2,65,92,724	59,90,557	56,53,86,749	28,89,12,528	0	3,77,01,411	0	32,66,13,939	23,87,72,810	25,58,72,054
Previous Year	50,73,96,238	3,73,88,344	0	54,47,84,582	24,75,85,243	0	4,13,27,289	0	28,89,12,532	25,58,72,050	25,98,10,995

*For the year ended**Dawar*



AIMIL PHARMACEUTICALS (INDIA) LIMITED - HO

SCHEDULE 11 : SCHEDULE OF FIXED ASSETS AND DEPRECIATION THEREON FOR THE YEAR ENDED 31st March, 2019

	GROSS BLOCK			DEPRECIATION				NET BLOCK			
	As At 01.04.2018	Additions	Sale Adjustment	As At 31.03.2019	Upto 31.03.2018	For the Year		Sale Adjustment	Upto 31.03.2019	As At 31.03.2019	As At 31.03.2018
						Additional	Current				
A. Land	2,17,36,440	4,08,744	0	2,21,45,184	1,04,74,624	0	10,91,419	0	1,15,66,043	1,05,79,141	1,12,61,816
B. Building	1,91,63,656	13,14,091	0	2,04,77,747	1,33,67,463	0	8,85,473	0	1,42,52,936	62,24,811	57,96,193
C. Plant & Machinery	1,43,38,343	23,57,504	0	1,66,95,847	96,74,231	0	37,41,154	0	1,34,15,385	32,80,463	46,64,112
D. Computers	5,35,30,339	0	0	5,35,30,339	4,15,65,118	0	34,42,459	0	4,50,07,577	85,22,762	1,19,65,221
E. Vehicles	1,09,13,776	3,06,550	0	1,12,20,326	92,97,410	0	98,591	0	93,96,001	18,24,325	16,16,366
F. Furniture & Fixtures	1,33,96,161	12,60,791	0	1,46,56,952	98,71,576	0	17,31,310	0	1,16,02,886	30,54,067	35,24,585
G. Office Equipment	7,39,565	0	0	7,39,565	7,13,648	0	0	0	7,13,648	25,917	25,917
H. Electric equipment	36,53,555	0	0	36,53,555	35,32,538	0	0	0	35,32,538	1,21,017	1,21,017
I. Cable Wires											
TOTAL (A)	13,74,71,835	56,47,681	0	14,31,19,516	9,84,96,608	0	1,09,90,406	0	10,94,87,014	3,36,32,502	3,89,75,227
Previous Year	12,96,09,430	78,62,405		13,74,71,835	8,53,86,791	0	1,31,09,821		9,84,96,612	3,89,75,223	4,42,22,639



for chairman
Danwaha

**AIMIL PHARMACEUTICALS (INDIA) LIMITED - NALAGARH****SCHEDULE 11 : SCHEDULE OF FIXED ASSETS AND DEPRECIATION THEREON FOR THE YEAR ENDED 31st March, 2019**

SCHEDULE 11 : SCHEDULE OF FIXED ASSETS AND DEPRECIATION											
	GROSS BLOCK			DEPRECIATION				NET BLOCK			
	As At 01.04.2018	Additions	Sale Adjustment	As At 31.03.2019	Upto 31.03.2018	For the Year		Sale Adjustment	Upto 31.03.2019	As At 31.03.2019	As At 31.03.2018
						Additional	Current				
A. Land	84,07,000			84,07,000		0		0	0	84,07,000	84,07,000
B. Building	17,23,01,256	1,01,04,342		18,24,05,598	6,19,91,656	0	1,12,03,782	0	7,31,95,436	10,92,10,162	11,03,09,600
C. Plant & Machinery	21,60,91,534	42,68,546		22,03,60,080	12,62,66,862	0	1,43,28,315	0	14,51,64,077	7,51,96,003	8,98,24,672
D. Computers	6,71,463	0		6,71,463	3,40,749	0	2,04,984	0	5,45,733	1,25,730	3,30,714
E. Vehicles				0		0		0	0	0	0
F. Furniture & Fixtures	36,85,039	63,78,028		1,00,63,067	17,33,847	0	9,03,534	0	26,37,382	74,25,685	19,51,192
G. Office Equipment	1,39,958	20,703		1,60,661	81,893	0	31,444	0	1,13,336	47,325	58,065
H. Electric equipment	25,940	0		25,940	913	0		0	0	25,940	25,027
I. Cable Wires		1,73,424		1,73,424	0	0	38,947	0	39,860	1,33,564	0
TOTAL (A)	40,13,22,190	2,09,45,043	0	42,22,67,233	19,04,15,920	0	2,67,11,006	0	22,16,95,824	20,05,71,409	21,09,06,270
Capital Work in Progress	59,90,557		59,90,557	0	0	0	0	0	0	0	0
TOTAL (B)	59,90,557	0	59,90,557	0	0	0	0	0	0	0	0
TOTAL (A+B)	40,73,12,747	2,09,45,043	59,90,557	42,22,67,233	19,04,15,920	0	2,67,11,006	0	22,16,95,824	20,05,71,409	21,09,06,270
Previous Year	37,77,86,808	2,95,25,939		40,73,12,747	16,21,98,452	0	2,82,17,468	0	19,04,15,920	21,68,96,827	21,55,88,356



for the comp
Danwaha



AIMIL PHARMACEUTICALS (INDIA) LIMITED

	AS AT 31.03.2019	AS AT 31.03.2018
SCHEDULE - 15 : SHORT - TERM LOANS AND ADVANCES (Unsecured considered good)		
Advances recoverable in cash or in kind or for value to be received	1,64,09,897	73,53,022
Security Deposits	16,30,50,000	11,32,93,998
Income Tax	1,06,72,978	1,06,72,978
	19,01,32,875	13,13,19,998
SCHEDULE - 16 : REVENUE FROM OPERATIONS		
Domestic Sales	3,01,23,20,654	2,68,24,17,360
Export sales	3,35,30,040	13,76,52,862
	3,04,58,50,694	2,82,00,70,222
SCHEDULE - 17 : OTHER INCOME		
Interest Received	4,49,363	7,30,895
Miscellaneous Income	99,00,629	1,15,00,654
	1,03,49,992	1,22,31,549
SCHEDULE - 18 : COST OF MATERIALS CONSUMED		
<u>Raw Material Consumed</u>		
Opening Stock	8,23,76,310	7,64,15,856
Add : Purchases during the year	48,08,51,424	39,27,57,913
Less : Closing Stock	9,85,71,498	8,23,76,310
Less : Expenses incurred on R & D	1,39,39,687	1,16,03,924
Raw Material Consumed	45,07,16,548	37,51,93,535
<u>Packing Material Consumed</u>		
Opening Stock	3,95,08,834	3,06,23,462
Add : Purchases during the year	0	20,02,16,984
Less : Closing Stock	4,16,40,759	3,95,08,834
Packing Material Consumed	-21,31,925	19,13,31,612
Total Rs...	44,85,84,623	56,65,25,147
SCHEDULE - 19 : Changes in Inventories of Finished Goods and WIP		
<u>Opening Stock</u>		
Finished Stock	15,09,80,028	20,04,08,191
Goods in Transit	4,09,07,498	4,91,72,856
	19,18,87,526	24,95,81,047
<u>Closing Stock</u>		
Finished Stock	6,10,05,080	15,09,80,028
Goods in Transit	12,27,130	4,09,07,498
	6,22,32,211	19,18,87,526
Total Rs...	12,96,55,315	5,76,93,521

Indrasp
Parvatha



**AIMIL PHARMACEUTICALS (INDIA) LIMITED**

	YEAR ENDED 31.03.2019	YEAR ENDED 31.03.2018
SCHEDULE - 20 : EMPLOYEE BENEFITS EXPENSE		
Salary , Wages & Bonus	54,00,59,018	50,50,30,094
Directors' Remuneration	1,10,97,600	92,97,600
Contribution to Provident and other Funds	3,30,74,574	3,31,72,339
Gratuity	26,27,225	14,38,776
Staff Welfare and other Amenities	74,84,435	1,11,91,926
	59,43,42,852	56,01,30,735
SCHEDULE - 21 : OTHER EXPENSES		
Rent, Rates & Taxes	3,51,57,975	44,04,650
Postage, Telegram & Telephones	53,79,379	45,06,896
Printing & Stationery	66,61,649	51,38,245
Conference Expenses	2,02,74,997	1,84,04,919
Electricity & water Expenses	31,22,608	66,68,371
Conveyance	1,54,29,015	1,20,16,954
Charity & Donation	1,80,600	2,00,800
Insurance Charges	7,64,015	7,74,116
Fees & Subscription	11,12,822	4,40,975
Legal & Professional Expenses	71,62,226	56,15,186
General Expenses	35,67,492	39,02,651
Diwali Expenses	13,77,974	11,34,185
Office Repair & Maintenance	32,24,534	51,52,488
Vehicle Running & Maintenance	40,06,035	45,05,521
Payment to Auditors - Audit Fees	16,00,000	16,00,000
- Other Expenses	5,25,200	4,86,800
Security Service Charges	13,70,922	11,95,884
Travelling Expenses	1,79,19,968	1,54,66,036
Books & Periodicals	1,32,911	1,69,844
Additional Sales Tax Paid	6,31,760	4,75,235
Royalty	96,16,241	90,23,257
Advertisement & Publicity	70,71,266	86,60,546
Octroi , Freight & Cartage Outward	5,62,25,054	5,45,68,769
Expiry & Breakages	5,39,99,872	4,09,39,734
Sales Promotion & Selling Expenses	84,97,43,276	88,34,38,787
C & F Commission & Expenses	3,33,27,517	3,92,07,966
Sales Incentive	8,89,91,721	8,39,67,420
TA/ DA Expenses	16,72,84,223	13,55,65,259
Freight & Cartage	76,48,759	58,91,998
Power & Fuel	3,93,27,667	3,28,03,440
Repair & Maintenance - Machinery	39,69,175	39,28,296
- Buildings	11,03,375	5,34,729
- Others	5,02,761	27,130
Other Manufacturing Expenses	46,32,033	18,96,534
Expenses incurred on R & D	1,54,63,186	1,16,03,924
	1,46,85,08,209	1,40,43,17,543
SCHEDULE - 22 : FINANCE COST		
Interest to Banks	5,05,24,316	3,55,21,987
Interest to Others	3,30,98,654	2,36,62,364
Bank Charges	38,65,288	24,20,953
	8,74,88,259	6,16,05,304

Page No. 14

Signature
Charuaka



Schedule 1: Significant Accounting Policies

(Annexure to and forming part of the Balance Sheet as on 31.03.2019 and Profit & Loss Account for the year ended on that date)

1.01 Basis of preparation

The accounts have been prepared on historical cost convention as a going concern on accrual basis, in accordance with the requirements of the Companies Act, 1956 and in accordance with the accounting principles generally accepted in India, and comply with the accounting standards notified under the Companies (Accounting Standards) Rules, 2006 (as amended), to the extent applicable. Accounting policies have been consistently applied and where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policy hitherto in use, such changes are suitably incorporated. The management evaluates all recently issued or revised accounting standards on an ongoing basis.

1.02 Presentation and disclosure of financial statements

The presentation and disclosure of the financial statements have been made in accordance with the revised Schedule VI notified by the Central Government vide notification no. S.O 447(E), dated 28th February 2011 (as amended by notification no. F No. 2/6/2008-CL-V, dated 30th March 2011) which has become effective for accounting periods commencing on or after 1st April 2011. The adoption of revised schedule VI does not impact recognition and measurement principles followed for preparation of financial statements. However it has significant impact on presentation and disclosures made in the financial statements. The Company has also reclassified the previous year figures in accordance with the requirements applicable in the current year.


1.03 Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles in India requires the management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the disclosure of contingent liabilities, at the end of the reporting period. Although these estimates are based on the management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcomes requiring a material adjustment to the carrying amounts of assets or liabilities in future periods.

1.04 Fixed Assets

- a) Tangible assets are stated at their original cost of acquisition including taxes, duties, freight, and other incidental expenses related to acquisition and installation of the concerned assets less accumulated depreciation and impairment losses, if any. Interest and other borrowing costs during construction period to finance qualifying fixed assets are capitalized.
- b) Subsequent expenditure related to an item of tangible asset is added to its book value only if it increases the future benefits from the existing asset beyond its previously assessed standard of performance. All other expenses on existing tangible assets, including day to day repair and maintenance expenditure are charged to the statement of profit and loss for the period during which such expenses are incurred.
- c) Preoperative expenditure and trial run expenditure accumulated as capital work in progress is allocated on the basis of prime cost of fixed assets in the year of commencement of commercial production.
- d) Intangible assets are recognized if it is probable that the future economic benefits that are attributable to the asset will flow to the Company and cost of the assets can be measured reliably.

For & on behalf of
Manu Sharma



1.05 Depreciation

- a) Depreciation has been provided on Written down value method at the rates and in the manner as prescribed in Schedule XIV of the Companies Act, 1956 which approximate the useful life of the assets estimated by the management. The residual values and useful life of assets are reviewed and adjusted, if appropriate, at each balance sheet date. Depreciation on fixed assets added/disposed off during the year is provided on pro-rata basis. Depreciation on assets for a value not exceeding Rs.5000 acquired during the year is provided at the rate of 100%.
- b) The cost and the accumulated depreciation on fixed assets sold or otherwise disposed off are removed from the stated values and resulting gain and losses are recognized in profit and loss account.

1.06 Inventories

- a) Raw materials, components, stores and spares are valued at lower of cost and net realizable value. However, materials and other items held for use in the production of inventories are not written down below cost if the finished products in which they will be incorporated are expected to be sold at or above cost. Cost of raw materials, components and stores and spares is determined on a moving weighted average basis.
- b) Work-in-progress and finished goods are valued at lower of cost and net realizable value. Cost includes direct materials and labour and a proportion of manufacturing overheads based on normal operating capacity. Cost of finished goods includes excise duty and is determined on a weighted average basis.
- c) The stocks of scrap materials have been taken at net realisable value.

1.07 Retirement Benefits

Contributions to defined contribution scheme such as provident fund etc. are charged to profit & loss account as incurred. The company also provides for retirement /Post Retirement benefits in form of gratuity, pensions and medical. Such benefits are recognized as an expense as and when incurred.


1.08 Revenue Recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the group and the revenue can be reliably measured. Revenue from sales are recognized when significant risks and rewards of ownership of the goods have passed to the buyer which coincides with delivery and are recorded net of returns and trade discount. Excise duty is deducted from revenue (gross) to arrive at revenue from operation (net). Sales are exclusive of sales tax and value added tax. Sales do not include inter-divisional transfers.

1.09 Earnings per Share

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares. The number of shares and dilutive shares are adjusted by issue of bonus shares, if any.

for the company
Baruah



1.10 Taxes on Income

Tax expense for the year comprises of current tax and deferred tax.

- a) Current tax is determined on the amount of tax payable in respect of taxable income for the period, using the applicable tax rates and tax laws in accordance with the provisions of Income Tax Act 1961.
- b) Deferred tax is recognized, subject to consideration of prudence, on timing differences, being difference between taxable and accounting income that originate in one period and are capable of reversal in one or more subsequent periods. Deferred tax is accounted for using the tax rates and laws that have been enacted or substantively enacted as on the Balance Sheet date. Deferred tax assets are recognized only to the extent that there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized. At each reporting date, the group re-assesses unrecognized deferred tax assets. It recognizes unrecognized deferred tax asset to the extent that it has become reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available against which such deferred tax assets can be realized.

1.11 Impairment of assets

The group assesses at each reporting date whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating unit's (CGU) net selling price and its value in use. The recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. Where the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining net selling price, recent market transactions are taken into account, if available. If no such transactions can be identified, an appropriate valuation model is used. Impairment losses of continuing operations, including impairment on inventories, are recognized in the statement of profit and loss. After impairment, depreciation is provided on the revised carrying amount of the asset over its remaining useful life.

1.12 Borrowing costs

Borrowing cost includes interest and other costs incurred in connection with the arrangement of borrowings and exchange differences arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost. Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the respective asset. All other borrowing costs are expensed in the period they occur.

1.13 Provisions and Contingent Liabilities

Provisions

A provision is recognized when the group has a present obligation as a result of past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Provisions are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the reporting date. These estimates are reviewed at each reporting date and adjusted to reflect the current best estimates.

For & on behalf of
Dr. Arunachal



Contingent Liabilities

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the group or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The company does not recognize a contingent liability.

for & the comp
Dawaka



Schedule 2: Notes to Accounts**(Annexure to and forming part of the balance sheet as on 31.03.2019 and Profit & Loss Account for the year ended on that date)****2.1 Cash and cash equivalents**

Cash and cash equivalents comprise cash at bank and in hand and short-term investments with an original maturity of three months or less.

2.2 Deferred Tax Liability

	Amount Rs.
W.D.V As per Companies Act, 1956	22,34,68,253
W.D.V As Per Income Tax Act, 1961	23,42,03,911
Difference	1,07,35,658
Deferred Tax Liabilities as on 31.03.2019	33,49,525
Deferred Tax Liabilities as on 31.03.2018	38,30,900
Provision to be made for FY 2017-18	(-) 4,81,375

2.3 Auditor's Remuneration consists of followings:


	<u>2018-19</u>	<u>2017-18</u>
Audit Fees	15,00,000	15,00,000
Tax Audit Fees	1,00,000	1,00,000
Other Matters	3,50,000	3,50,000
Other Expenses	<u>1,75,200</u>	<u>1,36,800</u>
TOTAL	21,25,200	20,86,800


2.4 Particulars of Remuneration Paid to Directors

	<u>2018-19</u>	<u>2017-18</u>
Managing Director	36,00,000	27,00,000
Other Directors	<u>74,97,600</u>	<u>65,97,600</u>
TOTAL	110,97,600	92,97,600

2.5 The Earning Per Share (EPS) comes to Rs. 46.09 per share (Previous year Rs 40.87 per share on 8,17,560 Equity Shares) on 8,17,560 Equity Shares on annual basis.

For and behalf of the Board
Ambani & Associates LLP
Chartered Accountants
FRN-016923N


(Hitesh Ambani)
M.No.- 506267
Designated Partner


Kanwal Kumar Sharma
(Managing Director)


Pankaj Marwaha
(Director - Marketing)


Ram Sawroop Sharma
(Chief Financial Officer)

Place: New Delhi
Date: 28.06.2019

Annexure 'A' to Notes to Accounts

Accounting Standard (AS-18) – "Related Party Disclosure"

S.No	Description Of Related Party	Name of Related Party
1	Name of Associate Company	Aimil Marketing Services Pvt. Ltd.
2	Key Management Personnel	a. Mr. K. K.Sharma - Managing Director b. Mr Pankaj Marwaha - Director Marketing c. Mrs Manjula Sharma - Director d. Mrs. Subhash Sharma - Director e. Mr. Satya Prakash Srivastava - Director
3	Relatives of Key Management Personnel	a. Mr. Ikshit Sharma - Son of Managing Director b. Mr. Prince Joshi - Son of Director c. Mr. Sanchit Sharma - Son of Managing Director d. Mrs. Pooja Sharma - Wife of Mr. Ikshit Sharma e. Mrs. Sugandha Marwaha - Wife of Mr. Sanchit Sharma f. Mrs. Priya Marwaha - Wife Of Mr. Pankaj Marwaha g. Mrs. Nitika Kohli - Daughter of MD Sir h. Mrs. Kshmta Srivastava - Daughter of Director i. Mrs. Rashmi Srivastava - Wife of Director

(Figures are in '000)

Particulars	Key Management Personnel		Relatives of KMP	
	31/03/2019	31/03/2018	31/03/2019	31/03/2018
Director's Remuneration				
Mr. K. K. Sharma	3600.00	2700.00		
Mr. Pankaj Marwaha	2400.00	2400.00		
Mrs. Manjula Sharma	3600.00	2700.00		
Mrs. Subhash Sharma	600.00	600.00		
Mr. S. P. Srivastava	897.60	897.60		

Salary				
Mr. Ikshit Sharma			3600.00	2700.00
Mr. Prince Joshi			804.60	804.60
Mr. Sanchit Sharma			3600.00	2700.00
Mrs. Pooja Sharma			3600.00	2700.00
Mrs. Sugandha Marwaha			3600.00	2700.00
Mrs. Priya Marwaha			961.44	760.96
Mrs. Nitika Kohli			2600.00	750.00
Mrs. Rashmi Srivastava			786.60	786.60
Mrs. Kshmta Srivastava			0.00	359.55

G. C. Sharma

Marwaha





REGD. OFFICE

2994/4, Street No. 17, Ranjeet Nagar, New Delhi - 110008

PH. : 011-66410000, 25701203, 25703041, FAX : 011-25703064, 25703635

Web : www.aimilpharmaceuticals.com Mail : corporate@aimilpharmaceuticals.com

WORKS

UNIT-I :

A-13/2, Nariana Industrial Area, Phase-I, New Delhi-110 028, INDIA ,

Ph: +91-11-25790778, 25792172, 25790960, 25793226

UNIT-II :

Saini Majra, Ropar Nalagarh Road, Tehsil Nalagarh, Distt. Solan (HP), INDIA,

Ph : +91-1795-265438, 265966, 265967